Document Detail

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
MedLine Citation:
PMID:  9305231     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Mometasone furoate (Nasonex), in a new once-daily aqueous nasal spray formulation, has been shown to be as effective and well-tolerated as twice-daily beclomethasone dipropionate aqueous nasal spray in treating symptoms of seasonal allergic rhinitis and perennial rhinitis. OBJECTIVE: To compare the effectiveness and tolerability of mometasone furoate to placebo and to fluticasone propionate aqueous nasal spray, all treatments administered once-daily, in patients with perennial rhinitis. METHODS: This was a 3-month, randomized, double-blind, double dummy, parallel group study in 550 patients, aged 12 to 77 years, at 25 centers in Canada, Latin America, and Europe. Patients allergic to at least one perennial allergen, with confirmed allergy history, skin test positivity, and moderate to severe symptomatology, were eligible to receive one of the following treatments, once daily in the morning: mometasone furoate 200 micrograms, fluticasone propionate 200 micrograms, or placebo. The primary efficacy variable was the change from baseline in total AM plus PM diary nasal symptom score over the first 15 days of treatment. RESULTS: Four hundred fifty-nine patients were valid for efficacy. For the primary efficacy variable, mometasone furoate was significantly (P < .01) more effective than placebo and was not statistically different from fluticasone propionate (percent reductions from baseline were 37, 39, and 22 for mometasone furoate, fluticasone propionate, and placebo, respectively). Generally, similar trends were seen for physician-evaluated total nasal symptoms, and patient-rated and physician-rated overall condition and response to therapy. Overall, mometasone furoate was at least as effective as fluticasone propionate at equivalent doses. There was no evidence of tachyphylaxis. All treatments were well tolerated. CONCLUSION: Mometasone furoate and fluticasone propionate adequately controlled symptoms of perennial rhinitis and were well tolerated.
M Mandl; K Nolop; B N Lutsky
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  79     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-10-06     Completed Date:  1997-10-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  237-45     Citation Subset:  IM    
Department of Medicine, St. Paul's Hospital, University of British Colombia, Vancouver, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Androstadienes / administration & dosage*,  therapeutic use*
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage,  therapeutic use
Double-Blind Method
Drug Administration Schedule
Middle Aged
Pregnadienediols / administration & dosage*,  therapeutic use*
Rhinitis, Allergic, Perennial / drug therapy*
Reg. No./Substance:
0/Androstadienes; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Pregnadienediols; 83919-23-7/mometasone furoate; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Systemic allergic reaction following ingestion of undeclared peanut flour in a peanut-sensitive woma...
Next Document:  Allergic reactions to anisakis simplex parasitizing seafood.